Fagron (OTCMKTS:ARSUF) is a global pharmaceutical compounding company that supplies raw materials, equipment and services to compounding pharmacies, hospitals and healthcare practitioners. Its portfolio encompasses a range of pharmaceutical ingredients, dosage forms and specialized compounding solutions designed to meet patient-specific needs. The company supports the preparation of customized medications in areas such as dermatology, pain management, hormone replacement therapy and veterinary medicine, providing both sterile and non-sterile compounding products.
Headquartered in Rotterdam, the Netherlands, Fagron operates in more than 55 countries across Europe, the Americas, Asia-Pacific and the Middle East & Africa. The organization maintains a network of local laboratories and logistics centers to ensure compliance with regional regulations and to expedite delivery of critical compounding materials. Through its subsidiaries, Fagron offers technical training, regulatory consulting and quality assurance services, helping pharmacies and healthcare facilities to maintain high standards of safety and efficacy.
Since its founding in the early 2000s, Fagron has grown through organic expansion and targeted acquisitions, broadening its product range and geographic footprint. While the company is listed on Euronext Brussels, its American Depositary Receipts trade on the over-the-counter market under the symbol ARSUF. Fagron’s management team blends expertise in pharmaceutical science, supply chain operations and international business development to drive innovation in personalized medicine and to support the evolving needs of compounding professionals worldwide.
AI Generated. May Contain Errors.
